DUBLIN , Sept. 12, 2022 /PRNewswire/ -- The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2022" report has been added to ResearchAndMarkets.com's offering.
Exosome technologies have been developing rapidly in recent years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine, and regenerative medicine. In particular, cancer-derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.
The cargo contained within exosomes can offer prognostic information for a range of diseases - including cardiovascular, renal, neurodegenerative, and metabolic diseases - as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.
Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears, and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient's response to a specific course of treatment.
Exosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient's exosomes can be isolated, modified with the appropriate siRNA or protein, and injected back into the patient for treatment. Numerous approaches are being researched for creating drug-loaded exosomes and exosomes themselves can exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.
For these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to credit exosomes for a range of promising traits.
To date, three pharma companies (Takeda, Jazz Pharmaceuticals, and Roche Pharmaceutical Company) have signed partnership deals with exosome companies offering payment terms structured to deliver at or around $1 billion dollars . Within the past 5 years, there have been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 landmark acquisitions.
Today the exosome industry is witnessing:
A surging number of scientific papers investigating exosomes and their applications
Rising numbers of clinicals trials investigating exosome therapeutics and diagnostics
Swelling appetite among investors for exosome technology
An increasingly competitive IP environment
A diverse range of co-development partnerships
Proliferating numbers of exosome competitors in all major life science markets worldwide
This global strategic report about the exosome industry reveals:
The clinical pipeline for exosome therapeutics
Clinical trial activity by type, region, phase, and sponsor
Exosome industry events, including M&A activity, financing events, and IPOs
Strategic partnerships and co-development agreements
Competitors composing the global marketplace, including core technologies and products under development
Market size determinations by market segment, with forecasts through 2030
Exosome industry trends, competitive opportunities, and future directions.
3. EXOSOME ENGINEERING: THE NEW PLATFORM
4. MSC-DERIVED EXOSOMES IN REGENERATIVE MEDICINE
6. COMMERCIALLY AVAILABLE EXOSOME RESEARCH TOOLS
10. CURRENT STATUS OF EXOSOME MANUFACTURING
14. APPLICATION OF EXOSOMES IN VACCINE DEVELOPMENT
15. CURRENT STATUS OF EXOSOME INDUSTRY
17. PROFILES OF EXOSOME MARKET COMPETITORS Companies Mentioned
Cell Factory BVBA/Esperite NV
For more information about this report visit https://www.researchandmarkets.com/r/vjj43q
Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-exosome-market-report-2022-potential-in-cell-free-therapeutics-presents-lucrative-opportunities-301621855.html
Stéphane Bancel discusses the company’s latest Covid shot and prospects for using mRNA in seasonal flu vaccines and personalized treatments for cancer
Investors have lost patience with the slow-paced clinical trials of genetic therapies, and some are using the upbeat news to exit Intellia and peers.
In a recent interview with PEOPLE, the couple, whose real-life love story was portrayed in The Big Sick, opened up about what it's like to be in the immunocompromised community
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
Intellia Therapeutics said two of its experimental Crispr treatments produced positive results in early-stage trials.
In that spirit, let's examine two healthcare stocks that seem to have the tools to provide solid returns over the long term: Eli Lilly (NYSE: LLY) and Teladoc Health (NYSE: TDOC). Eli Lilly seems to excel in both areas. Take one of the company's most recent approvals: Mounjaro, a therapy used to control blood glucose levels in patients with type 2 diabetes.
Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. But CRISPR stocks sank.
A San Francisco-based immunology company that wants to help eradicate infectious disease globally has expanded its footprint in St. Louis, opening a new $41 million office within the Cortex innovation district. It says the new facility will be critical to advancing research to treat several infectious diseases, including Covid-19.
Omeros Corp (NASDAQ: OMER) reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID Trial. The company said that in approximately half of the patients died in the narsoplimab group, and narsoplimab was not given or was prematurely stopped, with those patients dying 9 to 35 days later. Omeros adds that despite narso
J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.
By M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Moving lead assets and earlier stage candidates forward … ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing therapies for a range of conditions focused on oncology/hematology, central nervous system (CNS) and ophthalmology, provided an update in a letter to shareholders this week. With a broad pipeline of
One standout in a gloomy stock market this week was Ventyx Biosciences (NASDAQ: VTYX). According to data compiled by S&P Global Market Intelligence, the clinical-stage biotech's shares soared more than 58% higher during the period, thanks to the approval of a drug that hasn't actually been developed by the company. The treatment in question is Bristol Myers Squibb's deucravacitinib (brand name: Sotyktu), which was approved by the U.S. Food and Drug Administration (FDA) last Friday.
How do you fix a forgetful memory? Neurologist shares brain exercises to keep memory sharp, including reading fiction, cooking from recipes and playing games.
Sen. Lindsey Graham has proposed legislation that would institute a national ban on abortion after 15 weeks, meeting resistsance from both sides of the aisle. Rep. Pramila Jayapal joins Katie Phang to discuss.
Two COVID-19 antibody therapies are no longer recommended by the World Health Organization (WHO), on the basis that Omicron and the variant's latest offshoots have likely rendered them obsolete. On Thursday, WHO experts said they strongly advised against the use of the two therapies in patients with COVID-19, reversing previous conditional recommendations endorsing them, as part of a suite of recommendations published https://www.bmj.com/content/370/bmj.m3379 in the British Medical Journal. GSK and partner Vir Biotechnology's sotrovimab - which has generated billions in sales and became one of the British drugmaker's top sellers last year - was pulled off the U.S. market by the U.S. Food and Drug Administration (FDA) in April.
Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.
Here's what experts say about getting the two vaccines at once.
The Health District is now offering Moderna and Pfizer BioNTech Covid-19 bivalent booster shots for county residents 12 and older.
Gilead Sciences Inc (NASDAQ: GILD) announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury (remdesivir) for severe COVID-19. WHO continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization. The WHO conditional recommendation is mainly driven by the final results of the WHO-sponsored SOLIDARITY study, which showed a statistically significant 17% lowe
Lawmakers hear from scientists about advancements to slow down the aging process